These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38288888)

  • 1. Assessing the impact of atrial fibrillation on symptoms and quality of life in hypertrophic cardiomyopathy.
    Rowin EJ; Wadid M; Maron MS; White M; Hook BG; Harnish P; Silver JS; Reynolds MR; Maron BJ
    J Cardiovasc Electrophysiol; 2024 Apr; 35(4):654-663. PubMed ID: 38288888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy.
    Rowin EJ; Link MS; Maron MS; Maron BJ
    Circulation; 2023 Nov; 148(22):1797-1811. PubMed ID: 38011245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy.
    Rowin EJ; Hausvater A; Link MS; Abt P; Gionfriddo W; Wang W; Rastegar H; Estes NAM; Maron MS; Maron BJ
    Circulation; 2017 Dec; 136(25):2420-2436. PubMed ID: 28916640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcatheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy: Long-term results and clinical outcomes.
    Castagno D; Di Donna P; Olivotto I; Frontera A; Calò L; Scaglione M; Arretini A; Anselmino M; Giustetto C; De Ferrari GM; Cecchi F; Haissaguerre M; Gaita F
    J Cardiovasc Electrophysiol; 2021 Mar; 32(3):657-666. PubMed ID: 33428271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: atrial fibrillation type determines the success rate.
    Derejko P; Polańska M; Chojnowska L; Michałowska I; Wójcik A; Piotrowicz E; Lech A; Kłopotowski M; Baranowski R; Przybylski A; Bilińska M; Sierpiński R; Walczak F; Szumowski L
    Kardiol Pol; 2013; 71(1):17-24. PubMed ID: 23348529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy.
    Bunch TJ; Munger TM; Friedman PA; Asirvatham SJ; Brady PA; Cha YM; Rea RF; Shen WK; Powell BD; Ommen SR; Monahan KH; Haroldson JM; Packer DL
    J Cardiovasc Electrophysiol; 2008 Oct; 19(10):1009-14. PubMed ID: 18479329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy.
    Kubo T; Baba Y; Ochi Y; Hirota T; Yamasaki N; Kawai K; Yamamoto K; Kondo F; Bando K; Yamada E; Furuno T; Yabe T; Doi YL; Kitaoka H
    ESC Heart Fail; 2021 Dec; 8(6):5022-5030. PubMed ID: 34472710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of atrial fibrillation in hypertrophic cardiomyopathy: a systematic review.
    Alphonse P; Virk S; Collins J; Campbell T; Thomas SP; Semsarian C; Kumar S
    Clin Res Cardiol; 2021 Apr; 110(4):544-554. PubMed ID: 32880676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression.
    Di Donna P; Olivotto I; Delcrè SD; Caponi D; Scaglione M; Nault I; Montefusco A; Girolami F; Cecchi F; Haissaguerre M; Gaita F
    Europace; 2010 Mar; 12(3):347-55. PubMed ID: 20173211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial substrate characterization in patients with atrial fibrillation and hypertrophic cardiomyopathy: Evidence for an extensive fibrotic disease.
    Efremidis M; Bazoukis G; Vlachos K; Prappa E; Anastasakis A; Megarisiotou A; Dragasis S; Asvestas D; Mililis P; Saplaouras A; Efremidis T; Batsouli A; Zimpounoumi N; Valkanas K; Sideris A; Letsas KP
    J Electrocardiol; 2021; 69():87-92. PubMed ID: 34619440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis.
    Providencia R; Elliott P; Patel K; McCready J; Babu G; Srinivasan N; Bronis K; Papageorgiou N; Chow A; Rowland E; Lowe M; Segal OR; Lambiase PD
    Heart; 2016 Oct; 102(19):1533-43. PubMed ID: 27234160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of atrial fibrillation in hypertrophic cardiomyopathy.
    Hematpour K; Steinberg JS
    Anadolu Kardiyol Derg; 2006 Dec; 6 Suppl 2():44-8. PubMed ID: 17162270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catheter ablation of atrial fibrillation in patients with and without hypertrophic cardiomyopathy: systematic review and meta-analysis.
    Ezzeddine FM; Agboola KM; Hassett LC; Killu AM; Del-Carpio Munoz F; DeSimone CV; Kowlgi GN; Deshmukh AJ; Siontis KC
    Europace; 2023 Aug; 25(9):. PubMed ID: 37595138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy: Treatment Strategy, Characteristics of Consecutive Atrial Tachycardia and Long-Term Outcome.
    Dinshaw L; Münkler P; Schäffer B; Klatt N; Jungen C; Dickow J; Tamenang A; Schleberger R; Pecha S; Pinnschmidt H; Patten M; Reichenspurner H; Willems S; Meyer C
    J Am Heart Assoc; 2021 Feb; 10(3):e017451. PubMed ID: 33455428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy.
    Olivotto I; Cecchi F; Casey SA; Dolara A; Traverse JH; Maron BJ
    Circulation; 2001 Nov; 104(21):2517-24. PubMed ID: 11714644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device.
    Wilke I; Witzel K; Münch J; Pecha S; Blankenberg S; Reichenspurner H; Willems S; Patten M; Aydin A
    J Cardiovasc Electrophysiol; 2016 Jul; 27(7):779-84. PubMed ID: 27060297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrid versus catheter ablation for Hypertrophic CardioMyopathy with Atrial Fibrillation (HCM-AF): study protocol for a randomised controlled trial.
    Tang Y; Li L; Chen S; Xue Y; Guo H; Song L; Tang M; Yao Y; Zheng Z
    BMJ Open; 2024 Oct; 14(10):e089284. PubMed ID: 39384237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management.
    Garg L; Gupta M; Sabzwari SRA; Agrawal S; Agarwal M; Nazir T; Gordon J; Bozorgnia B; Martinez MW
    Heart Fail Rev; 2019 Mar; 24(2):189-197. PubMed ID: 30456592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrial Fibrillation in Hypertrophic Cardiomyopathy.
    Vaidya K; Semsarian C; Chan KH
    Heart Lung Circ; 2017 Sep; 26(9):975-982. PubMed ID: 28602671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis.
    Zhao DS; Shen Y; Zhang Q; Lin G; Lu YH; Chen BT; Shi LS; Huang JF; Lu HH
    Europace; 2016 Apr; 18(4):508-20. PubMed ID: 26612881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.